Aptevo Therapeutics Inc.: From Biotech Beacon to Stock Plunge Amid APVO711 Challenges
Aptevo Therapeutics Inc’s stock has plummeted nearly 99% from its peak, raising questions about the company’s future and the viability of its flagship program, APVO711.
2 minutes to read